The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 24.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42.
Artivion, Inc. AORT
Clears both ethical standardsAn entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Artivion, Inc.
read at $25.06
Artivion, Inc. holds its Markup at $25.06.
- PHPhase · the trend structure carries the Markup label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · passes the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 13 days |
| Price | $25.06 |
| Valuation | 100.24 trailing · 34.81 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 1.25 |
The opportunity · what the numbers say it is worth
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
| Revenue growth | 17.50% |
| Profit margin | 2.55% |
| Debt to equity | 57.31 |
| Analyst consensus | None · 8 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
Used by most halal investing apps ✓ PASSES
The one Titan applies ✓ PASSES
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Fail
- Interest-bearing cash Interest-bearing cash and securities are of assets, above the one-third limit. Fail
- Receivables Money owed to the company is of assets, above the 49% limit. Fail
- Revenue purity Only 0.0% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Heart valves alone do not make a bargain
Picture a surgeon fitting an On-X valve into a patient. The procedure saves a life, yet the business behind it earns just three pence on every pound of sales while returning only three percent on equity. Artivion grows revenue at eighteen percent, yet trades at thirty-five times forward earnings with an unknown competitive moat. Those figures leave no margin for error once growth slows.
We pass because the seventeen percent gap between the twenty-five dollar share price and our twenty-nine dollar fair value does not compensate for thin profitability and an elevated multiple. Analyst targets sit higher, yet our screen finds nothing compelling once the low returns and high valuation are weighed together. Ethical clearance removes one objection but creates no investment case on its own.
Low margins leave little room for execution slips or reimbursement pressure, and an unknown moat offers scant protection if larger device makers expand. The combination keeps the opportunity rating at none despite the clean ethical screen. Analysis, not advice.
| Forward P/E | 34.8x priced for continued growth |
| Trailing P/E | 100.2x expensive — the price assumes strong growth ahead |
| Revenue growth | 17.5% steady growth |
| Profit margin | 2.5% barely profitable |
| Return on equity | 3.1% a modest return on shareholder capital |
| Debt to equity | 0.57 moderate, manageable leverage |
| Current ratio | 3.86 comfortably covers its short-term bills |
| Beta | 1.25 moves a little more than the market |
| Market cap | $1.2B |
| Employees | 1,800 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in AORT's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
AORT trades on the NYSE. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (8 analysts) rates it strong buy, with a mean price target of $42.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $23.81 | -14.0% | · | $860 | -14.0% |
| 2 months | $37.63 | -45.6% | · | $544 | -45.6% |
| 3 months | $36.17 | -43.4% | · | $566 | -43.4% |
| 6 months | $45.48 | -55.0% | · | $450 | -55.0% |
| 1 year | $29.24 | -30.0% | · | $700 | -30.0% |
| 2 years | $23.27 | -12.0% | · | $880 | -12.0% |
| 3 years | $15.49 | +32.2% | · | $1,322 | +32.2% |
| 5 years | $29.06 | -29.6% | · | $704 | -29.6% |
Historical returns from market close data. Past performance does not guarantee future results.